Cargando…
Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice
Background: Two anti-cancer agents, doxorubicin (DOX) and trastuzumab (TRZ), are commonly used in the management of breast cancer in women. Despite their efficacy in reducing the morbidity and mortality of individuals with breast cancer, the use of these agents is limited by adverse cardiotoxic side...
Autores principales: | Eekhoudt, Cameron R., Bortoluzzi, Tessa, Varghese, Sonu S., Cheung, David Y. C., Christie, Simon, Eastman, Skyler, Mittal, Ishika, Austria, J. Alejandro, Aukema, Harold M., Ravandi, Amir, Thliveris, James, Singal, Pawan K., Jassal, Davinder S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139942/ https://www.ncbi.nlm.nih.gov/pubmed/35621631 http://dx.doi.org/10.3390/curroncol29050241 |
Ejemplares similares
-
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
por: Akolkar, Gauri, et al.
Publicado: (2015) -
Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
por: Varghese, Sonu S., et al.
Publicado: (2021) -
IL-10 attenuates OxPCs-mediated lipid metabolic responses in ischemia reperfusion injury
por: Bagchi, Ashim K., et al.
Publicado: (2020) -
Interleukin-10 Mitigates Doxorubicin-Induced Endoplasmic Reticulum Stress as Well as Cardiomyopathy
por: Malik, Akshi, et al.
Publicado: (2022) -
Coronary stent on the move
por: Bews, Hilary, et al.
Publicado: (2021)